These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 21087351

  • 1. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, Yi Z, Liu M, Pang X.
    Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
    [Abstract] [Full Text] [Related]

  • 2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 3. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
    Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C, Fotsis T.
    Cancer Res; 2004 Nov 01; 64(21):7936-46. PubMed ID: 15520200
    [Abstract] [Full Text] [Related]

  • 4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 5. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y, He L, Zhang L, Chen J, Yi Z, Zhang J, Liu M, Pang X.
    J Pharmacol Exp Ther; 2011 Nov 15; 339(2):403-11. PubMed ID: 21828260
    [Abstract] [Full Text] [Related]

  • 6. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT.
    Int J Oncol; 2010 Oct 15; 37(4):1023-30. PubMed ID: 20811725
    [Abstract] [Full Text] [Related]

  • 7. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS.
    Cancer Lett; 2013 May 10; 332(1):74-82. PubMed ID: 23348694
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase.
    Sun ZJ, Chen G, Zhang W, Hu X, Huang CF, Wang YF, Jia J, Zhao YF.
    J Pharmacol Exp Ther; 2010 Aug 10; 334(2):500-12. PubMed ID: 20484154
    [Abstract] [Full Text] [Related]

  • 10. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.
    Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W, Guo Y.
    Oncogene; 2009 Sep 24; 28(38):3412-22. PubMed ID: 19597469
    [Abstract] [Full Text] [Related]

  • 11. Role of afadin in vascular endothelial growth factor- and sphingosine 1-phosphate-induced angiogenesis.
    Tawa H, Rikitake Y, Takahashi M, Amano H, Miyata M, Satomi-Kobayashi S, Kinugasa M, Nagamatsu Y, Majima T, Ogita H, Miyoshi J, Hirata K, Takai Y.
    Circ Res; 2010 Jun 11; 106(11):1731-42. PubMed ID: 20413783
    [Abstract] [Full Text] [Related]

  • 12. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
    Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C, Broggini M, Iacobelli S, Potter BV, Innocenti P, Falasca M.
    Cancer Res; 2005 Sep 15; 65(18):8339-49. PubMed ID: 16166311
    [Abstract] [Full Text] [Related]

  • 14. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 15. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG, Kim TD, Li G, Yoon WH, Chae CB.
    Clin Cancer Res; 2005 Apr 01; 11(7):2651-61. PubMed ID: 15814646
    [Abstract] [Full Text] [Related]

  • 16. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways.
    Shen K, Ji L, Gong C, Ma Y, Yang L, Fan Y, Hou M, Wang Z.
    Biochem Pharmacol; 2012 Sep 15; 84(6):784-92. PubMed ID: 22771629
    [Abstract] [Full Text] [Related]

  • 17. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X, Wang X, Ye H, Peng A, Chen L.
    Cancer Chemother Pharmacol; 2012 Sep 15; 70(3):425-37. PubMed ID: 22814678
    [Abstract] [Full Text] [Related]

  • 18. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
    Zhong ZF, Hoi PM, Wu GS, Xu ZT, Tan W, Chen XP, Cui L, Wu T, Wang YT.
    J Ethnopharmacol; 2012 Jun 01; 141(2):721-7. PubMed ID: 21911050
    [Abstract] [Full Text] [Related]

  • 19. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma.
    Sun ZJ, Chen G, Zhang W, Hu X, Liu Y, Zhou Q, Zhu LX, Zhao YF.
    Mol Pharmacol; 2011 Jan 01; 79(1):106-18. PubMed ID: 20959361
    [Abstract] [Full Text] [Related]

  • 20. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.
    Angiogenesis; 2009 Jan 01; 12(3):287-96. PubMed ID: 19544081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.